Navigation Links
Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
Date:6/16/2008

Cato Research Signed as Strategic Partner for the Phase 3 Program

LA JOLLA, Calif., June 16 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company developing non-invasive, topically administered medications, today announced the initiation of its Phase 3 clinical program for Ketotransdel(TM), its novel topical cream based non-steroidal anti-inflammatory drug ("NSAID") for pain. The Company has engaged Cato Research Ltd., a global contract research organization ("CRO"), as a strategic partner and as the CRO to conduct the Phase 3 clinical program.

The Company's randomized, double-blind, placebo controlled Phase 3 trial will evaluate the efficacy and safety of Ketotransdel(TM) for the topical treatment of acute pain from soft tissue injuries. Clinical sites are planned throughout the United States and potentially other regions, including Canada. The Company expects that Ketotransdel(TM), if approved by the U.S. Food and Drug Administration, could become the first topical NSAID cream product in the United States for acute pain management. The drug could address what the Company believes is a significant unmet medical need for patients and physicians seeking a potentially safer alternative to existing pain management approaches, such as oral NSAIDs.

"Advancing Ketotransdel(TM) into Phase 3 clinical studies is a significant milestone for our Company. Our top priority is to execute our clinical program as planned," said Dr. Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals. "For the conduct of the clinical trial we carefully evaluated only select top level CROs with extensive experience in the relevant pain area. We selected Cato Research not only due to their relationship as a strategic partner with us, but because of their cost efficient approach to the clinical program, expertise in the pain space and our direct access to their senior executive man
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
5. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
6. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
7. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
10. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
11. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Amerigen Pharmaceuticals Ltd. announces ... Ltd., has received Chinese FDA (CFDA) approval and ... Tablets into the China ... and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., ... US FDA approved and China CFDA certified oral ...
(Date:8/20/2014)... LOS ANGELES , Aug. 20, 2014   Easy Breathe ... today announced that its " Easy Blog " - has received ... the year.   "We are thrilled that so many ... Nick Weiss , CEO of Easy Breathe. "We,re committed to making ... use Easy Blog to stay informed about sleep apnea news ...
(Date:8/20/2014)... MUMBAI , August 20, 2014 ... owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), ... studies of a novel clinical development candidate, GBR ... discovered and developed by the Glenmark Biologics Research ... . GBR 1302 is based on Glenmark,s ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
... Response Rate and 100% Disease Control Rate Observed in ... Patients with Medullary Thyroid Cancer, CHICAGO, June ... from an ongoing phase 1 clinical trial of,XL184, a novel small ... The maximum tolerated dose (MTD) for,XL184 has been determined to be ...
... Recipients with Cancer, HERSHEY, Pa., June 1 ... cancer is challenging.,Clinicians must balance the need to ... of chemotherapeutic agents on a,patient,s immune system., ... will be,presented today at the American Transplant Congress ...
Cached Medicine Technology:Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity 2
(Date:8/21/2014)... AttorneyOne.com, a recognized authority on law, update ... the FDA on Dianeal Low Calcium (2.5mEq/L) Peritoneal ... August 15, that two lots of Dianeal Low Calcium ... II), by Baxter International Inc., are recalled ... The reason for the recall is the presence of ...
(Date:8/21/2014)... MISSOULA, Mont. (PRWEB) August 21, 2014 She ... struck blind and brain injured after a surgery to correct ... “He Works All Things Together…” author Rebecca Strom-Stewart shares her ... misguided good intentions that led to a miscarriage of justice ... trudge through the tunnel of darkness and into the light,” ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Michael E. ... his Judaic roots back to the Bluff City with recent ... Jews, even those in the United States,” says friend and ... through various outreach programs, such as providing in-house for the ... with Israel by serving in the local synagogue. And to ...
(Date:8/21/2014)... Recently nominated as the Women’s Radio Network’s ... to be the man he is today. Growing up, KC ... positive look on women, respecting them as professionals and individuals. Through ... thanks to a man who he had the pleasure of working ... KC Armstrong’s name will ring a bell to most of you ...
(Date:8/20/2014)... Top 10 Best SEO Hosting (Top10BestSEOHosting.com) ... announced Bluehost ( http://www.bluehost.com/track/seohosts ), MaxCDN, and Justhost ... high quality PHP hosting at affordable rates. , ... Hosting are unbiased and entirely independent, ensuring that ... During the recent years, web hosting industry has ...
Breaking Medicine News(10 mins):Health News:Dianeal Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:The Dramatic, Uplifting Story from a Brain Injured Woman 2Health News:WRNW1's KC Armstrong Expresses Thanks and Appreciation to Howard Stern 2Health News:New Reviews Of Cheap PHP Hosting Companies Unveiled By Top 10 Best SEO Hosting 2
... Women,s Health Study Reveals that Strawberries May Help Reduce ... Having Elevated Inflammation in ... are not only,delicious and nutrient-rich, new research from Harvard ... The new study found,that those who reported eating the ...
... Up-Time and Improved Overall ... Laboratory ... (http://www.siemens.com/diagnostics ) announced today,worldwide availability of version 2.0 software ... will be a required upgrade for,all existing customers and included ...
... stepping into the national limelight with the establishment ... Research., The new center, funded by a $10 ... Health (NIMH), will support interdisciplinary studies aimed at ... in the brain., The neurotransmitter serotonin is central ...
... Inc. (NYSE: MYL ),today announced the appointment ... of Global Technical Operations. Mr. Malik has served ... acquired a controlling stake in Matrix,Laboratories Limited (Matrix), ... As Head of Global Technical Operations, Mr. ...
... Inc. (NYSE: MYL ),today announced the appointment of ... East and Africa) following the completion,of Mylan,s acquisition of ... Barret most recently served as Region Director,EMEA, reporting to ... 2004,following his role as Area Director for Southern Europe, ...
... disease care, study finds , , TUESDAY, Oct. 2 (HealthDay ... rates of chronic disease in the United States, with ... a new study finds. , It,s an expensive problem, ... and heart disease account for some $100 to $150 ...
Cached Medicine News:Health News:Strawberry Consumption Associated with C-Reactive Protein Among Women: New Harvard Study 2Health News:Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software 2Health News:Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software 3Health News:Vanderbilt nets brain gene research center 2Health News:Vanderbilt nets brain gene research center 3Health News:Mylan Appoints Rajiv Malik as Executive Vice President, Head of Global Technical Operations 2Health News:Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa 2Health News:Obesity Driving Rising U.S. Health Costs 2Health News:Obesity Driving Rising U.S. Health Costs 3
This instrument measures intraocular pressure without,contacting. Alignment is performed semi-automatically....
... InfusO.R. Pump is a syringe ... in the administration of many ... procedures. It provides for the ... relaxants, and vasoactive drugs through ...
... Management System answers the day-to-day needs ... flexibility. From programming to data retrieval, ... management right where you want it. ... to help each patient become ambulatory ...
The FLO-GARD 6201 Volumetric Infusion Pump and the FLO-GARD 6301 Dual-Channel Volumetric Infusion Pump are industry standard in standard set infusion pump technology....
Medicine Products: